Journal of Pharmaceutical Research International

Introduction: Coronavirus belongs to the family coronaviridae that majorly affects the respiratory system this group of virus outbreak previously as SARS and MERS in various countries and recently as COVID-19. COVID-19 has symptoms like fever, dry cough, breathing problems, loss of smell and taste, body aches. COVID-19 has spread to 210 countries and infected 272.51 million people worldwide, reached over 5.34 million deaths. Treatment includes antivirals, antibiotics, Non Steroidal Anti-Inflammatory Drugs, corticosteroids.

Methodology: It is a hospital-based retro-prospective study was conducted for 6 months in the Inpatient department. 100 patients were taken who met the inclusion criteria. Data collected and evaluated, analyzed by open label study.

Results and Discussion: severe COVID-19 can develop systemic inflammatory responses that can lead to lung injury and multisystem organ dysfunction. It has been proposed that the potent anti-inflammatory effects of corticosteroids might prevent or mitigate these deleterious effects. Both beneficial and deleterious clinical outcomes have been reported with the use of corticosteroids in patients with other pulmonary infections

From study, The Recovery% using steroids in the time period of 0-10 and 11-20 days was found to be 34 and 27% respectively. The Recovery percentage using steroids in the time period of 0-10 and 11-20 days was found to be 18 and 8% respectively. Dexamethasone was most commonly used in males and females, 77.08 and 84% respectively.

Conclusion: Considering beneficial effects of corticosteroids in COVID -19, prescribing steroids is safe by dose tapering continued up to 10days or hospital discharge